A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
Trial details
- Registry ID
- NCT07142811
- Phase
- Phase 2
The FDA approved Bulevirtide (BJT-778) on 22 May 2026.
Drug identity checked against registry records
Also recorded as BJT-778; Hepcludex
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionNCT07142811 | VIR | Phase 2 | Active not recruiting | 2029-03Estimated |
| A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideNCT07128550 | VIR | Phase 3 | Active not recruiting | 2026-12Estimated |
| Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideNCT07454837 | MIRM | Phase 2, Phase 3 | Recruiting | 2027-08-31Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2026-05-22Day | Bulevirtide | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761468", "applicant_as_listed_by_fda": "GILEAD SCIENCES INC", "brand_names": ["HEPCLUDEX"], "active_ingredients": ["BULEVIRTIDE-GMOD"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20260522", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |